



Announcement Summary

Entity name

MAYNE PHARMA GROUP LIMITED

Date of this announcement

Monday September 27, 2021

The +securities the subject of this notification are:

+Securities issued under an +employee incentive scheme that are subject to a restriction on transfer and are not being quoted on ASX until the restriction ends

Total number of +securities to be issued/transferred

ASX +security code	Security description	Total number of +securities to be issued/transferred	Issue date
MYXAN	PERFORMANCE RIGHTS	27,530,375	27/09/2021

Refer to next page for full details of the announcement



Part 1 - Entity and announcement details

1.1 Name of entity

MAYNE PHARMA GROUP LIMITED

We (the entity named above) give notice of the issue, conversion or payment up of the following unquoted +securities.

1.2 Registered number type

ABN

Registration number

76115832963

1.3 ASX issuer code

MYX

1.4 The announcement is

New announcement

1.5 Date of this announcement

27/9/2021



Part 2 - Issue details

2.1 The +securities the subject of this notification are:

+Securities issued under an +employee incentive scheme that are subject to a restriction on transfer and are not being quoted on ASX until the restriction ends

2.2a This notification is given in relation to an issue of +securities in a class which is not quoted on ASX and which:

has an existing ASX security code ("existing class")



Part 3B - number and type of +securities the subject of this notification (existing class) where issue has not previously been notified to ASX in an Appendix 3B

Additional +securities in an existing class issued under an +employee incentive scheme

ASX +security code and description

MYXAN : PERFORMANCE RIGHTS

Date the +securities the subject of this notification were issued

27/9/2021

Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class

Yes

Were any of the +securities issued to +key management personnel (KMP) or an +associate?

Yes

Provide details of the KMP or +associates being issued +securities.

Name of KMP	Name of registered holder	Number of +securities
Peter Paltoglou	Peter Paltoglou	2,236,975

Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms

- Rights are eligible for vesting over a period of up to five years from the date of the grant, subject to achievement of specific vesting condition hurdles.
- 20% of the grant eligible for vesting 1 year after the base test date, 30% eligible for vesting 2 years after the base test date and the balance eligible for vesting 3 years after the base test date, subject to achievement of the vesting conditions.
- The number / proportion of Rights that vest is based on the absolute Total Shareholder Return (TSR) over the period with 20% vesting if a TSR Compound Annual Growth (CAGR) of 8% is achieved, rising to 100% vesting for achievement of a TSR CAGR of 15%.
- If CAGR performance conditions are met, vesting occurs progressively and at continuously increasing hurdles.
- For further information refer to the 2021 Financial Accounts - <http://www.maynepharma.com/investor-relations/results-reports/>

Any other information the entity wishes to provide about the +securities the subject of this notification

- The base test date for Rights is set as 1 September 2021 and the expiry date is 30 September 2026
- The Base Test Price for the Rights is \$0.33.
- If the Rights are not exercised before the expiry date they will automatically lapse.
- There are no voting rights or rights to dividends whilst the participant holds a Right.



Issue details

Number of +securities

27,530,375

Part 4 - +Securities on issue

**Following the issue, conversion or payment up of the +securities the subject of this application, the +securities of the entity will comprise:
(A discrepancy in these figures compared to your own may be due to a matter of timing if there is more than one application for quotation/issuance currently with ASX for processing.)**

4.1 Quoted +Securities (Total number of each +class of +securities quoted)

ASX +security code and description	Total number of +securities on issue
MYX : ORDINARY FULLY PAID	1,764,840,757

4.2 Unquoted +Securities (Total number of each +class of +securities issued but not quoted on ASX)

ASX +security code and description	Total number of +securities on issue
MYXAN : PERFORMANCE RIGHTS	58,020,763
MYXAT : OPTION EXPIRING VARIOUS DATES EX VARIOUS PRICES	16,706,827



Part 5 - Other Listing Rule requirements

5.1 Were the +securities issued under an exception in Listing Rule 7.2 and therefore the issue did not need any security holder approval under Listing Rule 7.1?

No

5.2 Has the entity obtained, or is it obtaining, +security holder approval for the issue under listing rule 7.1?

No

5.2b Are any of the +securities being issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1?

Yes

5.2b.1 How many +securities are being issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1?

27,530,375

5.2c Are any of the +securities being issued without +security holder approval using the entity's additional 10% placement capacity under listing rule 7.1A (if applicable)?

No